Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Disparities in Participation in Interventional Clinical Trials for Myelodysplastic Syndromes

David P. Steensma, MD, Rami S. Komrokji, MD, Amy E. DeZern, MD, Gail J. Roboz, MD, Andrew M. Brunner, MD, Richard M. Stone, MD, John Barnard, PhD, Mikkael A. Sekeres, MD MS

Blood (2018) 132 (Supplement 1): 4374.

https://doi.org/10.1182/blood-2018-99-117538

Published: 2018

Journal Articles

Planned Interim Analysis of a Phase 2 Study Evaluating the Combination of Pracinostat, a Histone Deacetylase Inhibitor (HDACi), and Azacitidine in Patients with High/Very High-Risk Myelodysplastic Syndrome (MDS)

Michael K Keng, MD, Samer K. Khaled, MD, Brenda Cooper, MD, Erica D. Warlick, MD, David Ramies, MD, Silvia Mappa, MD, Ehab L. Atallah, MD

Blood (2018) 132 (Supplement 1): 4362.

https://doi.org/10.1182/blood-2018-99-112741

Published: 2018

Journal Articles

Under-Reporting of Patient Reported Outcome (PRO) in Clinical Trials

Liat Vidal-Fisher, MD MSc, Kelly K. Curtis, MD, Laura Vidal, MD, Keren R. Moss, MD

Blood (2018) 132 (Supplement 1): 3583.

https://doi.org/10.1182/blood-2018-99-114464

Published: 2018

Journal Articles

Expert Elicitation of Long-Term Survival for Pediatric Acute Lymphoblastic Leukemia Patients Receiving CTL019 in Eliana Phase II Study

Shannon Cope, MSc, Dieter Ayers, MSc, Tiffany Shih, PhD, Jie Zhang, PhD, Jeroen Jansen, PhD, Katherine Batt, MD MSc

Blood (2017) 130 (Supplement 1): 3377.

https://doi.org/10.1182/blood.V130.Suppl_1.3377.3377

Published: 2017

Journal Articles

Understanding the Preferences of Patients and Caregivers for Relapsed/Refractory Multiple Myeloma Treatment: A Mixed-Mode Patient-Centric Approach

Daniel Auclair, PhD, Carol Mansfield, PhD, Ajai Chari, MD, Craig E. Cole, MD, Mark A. Fiala, BS, Jonathan L. Kaufman, MD, Gregory Orloff, MD, David Siegel, MD PhD, Jeff A. Zonder, MD, Brennan Mange, Jennifer Yesil, MS, Mehul Dalal, PhD, Joseph Mikhael, MD

Blood (2017) 130 (Supplement 1): 5662.

https://doi.org/10.1182/blood.V130.Suppl_1.5662.5662

Published: 2017

Journal Articles

Predictors of Ponatinib Therapy Duration Among Real-World Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients in the US

Michael J. Mauro, MD, Lisa J. McGarry, MPH, Stephanie Lustgarten, PhD, Hui Huang, PhD MBA

Blood (2016) 128 (22): 3081.

https://doi.org/10.1182/blood.V128.22.3081.3081

Published: 2016

Journal Articles

Ponatinib in Chronic-Phase Chronic Myeloid Leukemia Patients: Final Report from a Phase 1 Trial

Michael J. Mauro, MD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Neil P. Shah, MD PhD, Dale L. Bixby, MD, Ian W. Flinn, MD PhD, Thomas O'Hare, PhD, Victor M. Rivera, PhD, Stephanie Lustgarten, PhD, Sergio Santillana, MD, Michael C. Heinrich, Brian J. Druker, MD, Michael W. Deininger, MD PhD, Moshe Talpaz, MD

Blood (2016) 128 (22): 3063.

https://doi.org/10.1182/blood.V128.22.3063.3063

Published: 2016

Journal Articles

Long-Term Follow-up of the Efficacy and Safety of Ponatinib in Philadelphia Chromosome-Positive Leukemia Patients with the T315I Mutation

Elias J. Jabbour, MD, Jorge E. Cortes, MD, Moshe Talpaz, MD, Michele Baccarani, MD, Michael J. Mauro, MD, Andreas Hochhaus, MD, Timothy P. Hughes, MD FRACP, FRCPA, MBBS, FAAHMS, Francois Guilhot, MD, Michael W. Deininger, MD PhD, Neil Shah, MD PhD, Dale L. Bixby, MD, Ian W. Flinn, MD PhD, Thomas O'Hare, PhD, Stephanie Lustgarten, PhD, Victor M. Rivera, PhD, Sergio Santillana, MD, Hagop M. Kantarjian, MD

Blood (2016) 128 (22): 3067.

https://doi.org/10.1182/blood.V128.22.3067.3067

Published: 2016

Journal Articles

What Do Patients Prioritize in Selecting Chronic Lymphocytic Leukemia (CLL) Treatments?

Carol Mansfield, PhD, Anthony Masaquel, MPH, PhD, Jessie Sutphin, Elisa S Weiss, PhD, Meghan E. Gutierrez, Jennifer Wilson, Jia Li, PhD, Carolina Reyes, PhD

Blood (2016) 128 (22): 1239.

https://doi.org/10.1182/blood.V128.22.1239.1239

Published: 2016

Journal Articles

Analysis of the Sub-Clonal Origins of Compound Mutations in Patients with Refractory Ph+ Malignancies Treated with Ponatinib

Justin R. Pritchard, PhD, Michael W. Schmitt, MD PhD, J. Graeme Hodgson, PhD, Stephanie Lustgarten, PhD, Shijie Tang, PhD, Lawrence A. Loeb, MD PhD, Jerald P. Radich, MD, Victor M. Rivera, PhD

Blood (2016) 128 (22): 1061.

https://doi.org/10.1182/blood.V128.22.1061.1061

Published: 2016

Journal Articles

Successful Engraftment of Donor Umbilical Cord Blood (UCB) Cells after Co-Transplantation of Nicord® ( Ex Vivo Expanded UCB Progenitor Cells with Nicotinamide) and a Second Unmanipulated Cord Blood Unit after Myeloablative Chemotherapy in Pediatric Patients with Severe Sickle Cell Disease

Suhag H Parikh, MD, Joel Brochstein, MD, Paul L. Martin, MD PhD, Mitchell E. Horwitz, MD, Einat Galamidi, MD, Iddo Peleg, MSc, MBA, Uri Goshen, M.MDSc., Aurelie Schwarzbach, MSc, David A. Snyder, PhD, Tony Peled, MSc, Joanne Kurtzberg, MD

Blood (2016) 128 (22): 3651.

https://doi.org/10.1182/blood.V128.22.3651.3651

Published: 2016

Journal Articles

Natural Killer Cell Expression of Natural Cytotoxicity Receptors Determines Relapse Risk in Elderly Patients with Acute Myeloid Leukemia Receiving Immunotherapy with Histamine Dihydrochloride and Interleukin-2

Anna Martner, PhD, Anna Rydström, PhD, Rebecca E Riise, Johan Aurelius, PhD, Mats L Brune, MD, Robin Foa, MD, Kristoffer Hellstrand, MD, Fredrik B Thorén, PhD

Blood (2014) 124 (21): 3680.

https://doi.org/10.1182/blood.V124.21.3680.3680

Published: 2014

Journal Articles

Patient Reported Outcomes Comparison of Chronic Immune Thrombocytopenia (ITP) Patients Switched to Promacta and Nplate

David J. Kuter, MD, DPhil, Feng Wang, Katie L Dawson, MD, MPH, Kelly M. Grotzinger, PhD, Cynthia P Macahilig

Blood (2011) 118 (21): 2220.

https://doi.org/10.1182/blood.V118.21.2220.2220

Published: 2011

Journal Articles

The Multiple Myeloma Research Consortium (MMRC): Accelerated Start up and Accrual Metrics Speeds Drug Development

Blood (2011) 118 (21): 1024.

https://doi.org/10.1182/blood.V118.21.1024.1024

Published: 2011

Journal Articles

The Multiple Myeloma Research Consortium (MMRC) Model: Reduced Time to Trial Activation and Improved Accrual Metrics.

Blood (2010) 116 (21): 3803.

https://doi.org/10.1182/blood.V116.21.3803.3803

Published: 2010

Journal Articles

Improvement in Right Ventricular Function Following 1 Year of Deferasirox Therapy in Patients with β-Thalassemia.

Gillian Smith, Dudley J. Pennell, John B. Porter, M. Domenica Cappellini, Lee Lee Chan, Amal El-Beshlawy, Yesim Aydinok, Hishamshah Ibrahim, Chi-Kong Lee, Vip Viprakasit, Mohsen Saleh Elalfy, Antonis Kattamis, Dany Habr, Gabor Domokos, Abdel Hmissi, Ali Taher

Blood (2009) 114 (22): 5106.

https://doi.org/10.1182/blood.V114.22.5106.5106

Published: 2009

NARROW

Disparities in Participation in Interventional Clinical Trials for Myelodysplastic Syndromes

Planned Interim Analysis of a Phase 2 Study Evaluating the Combination of Pracinostat, a Histone Deacetylase Inhibitor (HDACi), and Azacitidine in Patients with High/Very High-Risk Myelodysplastic Syndrome (MDS)

Under-Reporting of Patient Reported Outcome (PRO) in Clinical Trials

Expert Elicitation of Long-Term Survival for Pediatric Acute Lymphoblastic Leukemia Patients Receiving CTL019 in Eliana Phase II Study

Understanding the Preferences of Patients and Caregivers for Relapsed/Refractory Multiple Myeloma Treatment: A Mixed-Mode Patient-Centric Approach

Predictors of Ponatinib Therapy Duration Among Real-World Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients in the US

Ponatinib in Chronic-Phase Chronic Myeloid Leukemia Patients: Final Report from a Phase 1 Trial

Long-Term Follow-up of the Efficacy and Safety of Ponatinib in Philadelphia Chromosome-Positive Leukemia Patients with the T315I Mutation

What Do Patients Prioritize in Selecting Chronic Lymphocytic Leukemia (CLL) Treatments?

Analysis of the Sub-Clonal Origins of Compound Mutations in Patients with Refractory Ph+ Malignancies Treated with Ponatinib

Successful Engraftment of Donor Umbilical Cord Blood (UCB) Cells after Co-Transplantation of Nicord® ( Ex Vivo Expanded UCB Progenitor Cells with Nicotinamide) and a Second Unmanipulated Cord Blood Unit after Myeloablative Chemotherapy in Pediatric Patients with Severe Sickle Cell Disease

Natural Killer Cell Expression of Natural Cytotoxicity Receptors Determines Relapse Risk in Elderly Patients with Acute Myeloid Leukemia Receiving Immunotherapy with Histamine Dihydrochloride and Interleukin-2

Patient Reported Outcomes Comparison of Chronic Immune Thrombocytopenia (ITP) Patients Switched to Promacta and Nplate

The Multiple Myeloma Research Consortium (MMRC): Accelerated Start up and Accrual Metrics Speeds Drug Development

The Multiple Myeloma Research Consortium (MMRC) Model: Reduced Time to Trial Activation and Improved Accrual Metrics.

Improvement in Right Ventricular Function Following 1 Year of Deferasirox Therapy in Patients with β-Thalassemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only